"Anti-involution" + Beneficiary stocks from price increases are out, only 5 lagging stocks have seen significant increases in financing positions

According to incomplete statistics, as of August 22, among the more than 1,600 stocks that disclosed their half-year report forecasts for 2025, 64 stocks (hereinafter referred to as "anti-involution" + price increase beneficiary stocks) showed improved performance in the first half of this year (including net profit growth and turning losses into profits) due to reasons such as benefiting from the "anti-involution" actions or price increases. In terms of industry, among the "anti-involution" + price increase beneficiary stocks, as of August 22, only 5 stocks underperformed their respective Shenwan industries this year and had a financing balance increase of over 20% compared to the end of last year. Ranked by the increase in financing, they are HCSC, ZHONGJIN GOLD, CSSC Holdings, CSICPCL, and SJI, with HCSC seeing an increase in financing of over 120%. (Securities Times)